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INTRODUCTION
Colorectal cancer (CRC) is one of the most common and lethal 
malignancies in Korea [1]. However, despite the recent progress 
in diagnostic tools that has allowed for early cancer diagnosis, 
tumor recurrence remains a major problem. Approximately 30% 
of recurrent CRC involves liver metastasis. Liver resection is not 
indi cated in more than half of such recurrent cases. Recently, 
the survival rates in patients with liver metastasis from CRC 
have increased due to improvements in anticancer drugs. Two 
Purpose: In order to suggest optimal anticancer drugs for patient-tailored chemotherapy, we developed a colorectal 
cancer (CRC)-liver metastasis patient-derived tumor xenograft (PDTX) model. 
Methods: Tissue obtained from a patient with CRC-liver metastasis (F0) was transplanted in a nonobese female mouse 
with diabetic/severe combined immune deficiency (F1) and the tumor tissue was retransplanted into nude mice (F2). 
When tumor volumes reached ~500 mm3, the F2 mice were randomly divided into 4 groups (n = 4/group) of doxorubicin, 
cisplatin, docetaxel, and nontreated control groups. The tumor tissues were investigated using H&E staining, terminal 
deoxynucleotidyl transferase dUTP nick end labeling assays, and immu no histochemistry. To determine where the 
mutant allele frequencies varied across the different passages, we isolated genomic DNA from the primary tumor, liver 
metastasis, and PDTX models (F1/F2).
Results: The physiological properties of the tumor were in accord with those of the patient’s tumors. Anticancer drugs 
delayed tumor growth, inhibited proliferation, and caused apoptosis. Histological assessments revealed no observable 
heterogeneity among the intragenerational PDTX models. Target exon sequencing analysis without high-quality filter 
conditions revealed some genetic variations in the 83 cancer-related genes across the generations. However, when de 
novo mutations were defined as a total count of zero in F0 and ≥5 in F2, exactly prognostic impact of clone cancer profiling 
(EGFR, KRAS, BRAF, PIK3CA, NRAS, APC and TP53) were detected in the paired. 
Conclusion: A CRC liver metastasis PDTX model was established for the evaluation of chemotherapeutic efficacy. This 
model retained the physiological characters of the patient tumors and potentially provides a powerful means of assessing 
chemotherapeutic efficacy.
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of the standard treatments for CRC-liver metastasis include 
combinations of 5-fluorouracil with oxaliplatin (FOLFOX) 
or irinotecan (FOLFIRI) [2]. Recently, a phase II study on 
FOLFOXIRI plus panitumumab was reported [3]. However, this 
parti cular regimen is not suitable for all patients with CRC-liver 
meta stasis. Nevertheless, this initial chemotherapy plays an 
impor tant role in converting unresectable CRC-liver metastases 
to resectable metastases [4]. Therefore, individualized chemo-
ther apies might affect patient prognosis. 
To determine chemotherapeutic efficacy, an animal model 
that preserves the physiological properties of patient tumors 
must be established. This task might be achieved using a 
patient-derived tumor xenograft (PDTX) model that maintains 
the histopathological architecture of the original tumor. There-
fore, many researchers have attempted to develop a suitable 
PDTX model to predict therapeutic efficacy [5-7]. Such a model 
must offer a good platform for anticancer drug development 
and for monitoring drug response. Studies on this subject have 
increased over the past 10 years, especially for breast and lung 
cancer-derived xenograft models. Most developed PDTX models 
target primary cancers. Although metastatic disease leads 
to more mortality than primary cancer, comparatively little 
effort has been expended on developing xenograft models of 
metastasis. 
The purpose of this study was to characterize the histological 
and genomic fidelities of CRC-liver metastasis PDTX models and 
to evaluate the application of CRC-liver metastasis PDTX models 
to the development of patient-tailored chemotherapy. 
METHODS
Human liver tissue specimens
This collection of CRC-liver metastatic tissues was approved 
by the Institutional Review Board of Gangnam Severance 
Hospital (3-2014-0298). The samples were obtained from 
patients with pathologically proven CRC adenocarcinoma. 
Animals 
Female, nonobese diabetic (NOD)/severe combined immune 
deficiency (SCID) mice (5 to 8 weeks old) and female Balb/c nu/
nu mice (5 weeks old) were purchased from SLC (Japan SLC 
Inc., Hamamatsu, Japan). All animal care and experiments were 
performed in accordance with the guidelines issued by the 
Institutional Animal Care and Use Committee in University.
Patient-derived tumor transplantation 
Tissues were soaked in DMEM (GenDEPOT, Barker, TX, USA), 
transported on ice, and stored at 4°C until transplantation. 
Tumor tissues were dissected into 1 mm × 1 mm fragments [8]. 
After an NOD/SCID mouse was anesthetized with isoflurane, 
2 pieces of tumor specimens were implanted into the animal’s 
flank. After the tumor volumes reached 500 mm3, the patient-
derived tumor tissues were obtained from the NOD/SCID mouse 
(the PDTX [F1] model). These isolated tissues were divided into 
several pieces, and 1 piece was fixed in 4% paraformaldehyde 
solution for histology and immunohistochemistry. The dis-
sected pieces were re-engrafted into the flanks of Balb/c nu/nu 
mice (the PDTX [F2] model), while the remaining pieces were 
soaked in 5% dimethyl sulfide/ fetal bovine serum and stored 
in liquid N2. 
Histology and immunohistochemical staining
Tumor tissues were fixed in 4% paraformalin solution and 
embedded in paraffin. Paraffin blocks were sectioned into 5-µm 
slices. For histological observation, tissue sections were stained 
with hematoxylin and eosin (H&E). For immunohistochemistry, 
the tissue sections were deparaffinized in xylene, rehydrated 
with graded ethanol (from 100% to 70%), and treated with 3% 
H2O2 in methanol. The sections were then incubated with pri-
mary antibodies to Ki-67 (1:1000), CK7 (1:2000), and CK20 (1:500). 
All primary antibodies were obtained from DAKO (Carpin-
teria, CA, USA). After incubation with secondary antibodies, 
the tissue sections were treated with diaminobenzidine (DAB) 
solution and counter stained with hematoxylin. 
Tumor growth curve
Tumors were isolated from the NOD/SCID mouse (F1) and 
reimplanted into the flanks of nude mice. Two to 3 times per 
week, the tumor dimensions were measured using a caliper. 
Tumor volumes were calculated using the following formula:
Tumor volume (mm3) = (tumor length) × (tumor width)2/2 
To assess chemotherapeutic efficacy, nude mice (F2) were 
divided into 3 drug treatment groups and 1 control group (n 
= 4/group). Commercial drugs (cisplatin [CDDP], doxorubicin 
[DOX], and docetaxel [DTX], 10 mg/kg) were intravenously 
injected via a tail vein. Tumor sizes were measured 2–3 times 
per week. Body weights were recorded to evaluate toxicities.
TUNEL assay
After measuring tumor growth in F2 mice, the isolated tumor 
tissues were embedded in OCT compound (Leica Biosystems, 
Nussolch, Germany) and sectioned at 5 µm. Tissue sections 
were hydrated with 70% ethanol and treated with 3% H2O2 in 
methanol. The sections were then treated with TdT labeling 
buffer and incubated in TdT (Sigma-Aldrich, St. Louis, MO, 
USA)/biotinylated deoxyuridine (Roche Diagnostics, Mannheim, 
Germany). After reaction, the tissue sections were incubated 
with ABC complex and stained with DAB solution. 
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Target sequencing for 83 cancer-related genes
Genomic DNA was extracted from the primary tumor tissues 
and patient derived Xenograft (PDX) tissues using the DNeasy 
Blood and Tissue Kit (Qiagen, Valencia, CA, USA) according to the 
manufacture’s pro tocols. The DNA quality was assessed with 1% 
agarose gel elec tro phoresis and by the PicoGreen dsDNA Assay 
(Invitrogen, Carlsbad, CA, USA). The targeted panel was used to 
capture the target region covering 83 cancer-related genes. All of 
the coding exons of the following 72 genes were assessed for the 
detection of single-nucleotide variant (SNV), insertion/deletions 
(INDELs), and copy number variations (CNVs): ABL1, AKT1, 
AKT2, AKT3, ALK, APC, ARID1A, ARID1B, ARID2, ATM, AURKA, 
AURKB, BCL2, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDK6, 
CDKN2A, CSF1R, CTNNB1, DDR2, EGFR, EPHB4, ERBB2, ERBB3, 
ERBB4, EWSR1, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, 
GNA11, GNAS, GNAQ, HNF1A, HRAS, IDH1, IDH2, IGF1R, ITK, 
JAK1, JAK2, JAK3, KDR, KIT, KRAS, MDM2, MET, MLH1, MPL, 
MTOR, NF1, NOTCH1, NPM1, NRAS, NTRK1, PDGFRA, PDGFRB, 
PIK3CA, PIK3R1, PTCH1, PTCH2, PTEN, PTPN11, RB1, RET, ROS1, 
SMAD4, SMARCB1, SMO, SRC, STK11, SYK, TERT, TMPRSS2, 
TOP1, TP53, and VHL. In addition, some introns of the following 
5 genes were included in the detection of gene fusions: ALK, 
RET, ROS1, EWSR1, and TMPRSS2 (SureSelect, Agilent, Inc., USA). 
Approximately 200–500 ng of genomic DNA were prepared to 
construct libraries using the SureSelect targeted panel according 
to the manufacturer’s protocol. Briefly, the qualified genomic 
DNA sample was randomly fragmented by Covaris followed by 
adapter ligation, purification, hybridization, and polymerase 
chain reaction. The captured libraries were subjected to the 
Agilent 2100 Bioanalyzer to estimate the quality and were loaded 
onto an Illumina HiSeq2500 (TheragenEtex Bio Institute, Suwon, 
Korea) according to the manufacturer’s recommendations. The 
raw image files were processed by HCS1.4.8 for base-calling 
with default parameters. The sequences of each individual were 
generated as 101-bp paired-end reads.
Data analysis for target sequencing 
At the NGS data pre-processing step, the sequence reads 
were aligned to the human genome (hg19) using BWA-MEM [9]. 
In order to generate the analysis-ready BAM, the overall pre-
processing, including removal of duplication, local realignment, 
and recalibration, was performed using GATK Best Practice of 
Broad Institute [10]. 
At the variant discovery step, the SNVs and INDELs utilized 
3 open source callers (UnifiedGenotyper [11], LoFreq [12], and 
SNVer [13]) and Samsung SDS’s in-house callers. CNV and 
translocation were discovered with in-house callers developed 
by Samsung SDS. SNVs and INDELs were detected with an 
ensemble method that integrated three open source callers 
with an in-house caller. SNVs and INDELs were filtered using 
germ line mutations and false positive filters. SNVs with variant 
allele frequency (VAF) ≥ 5% and INDELs ≥ 10% were selected 
as the final results. CNVs between the tumor and pre processed 
normal data were analyzed using the depth of coverage for each 
target region. To calculate the absolute copy number, tumor 
purity and ploidy were estimated from a stati stical model 
using log2 ratio values and SNV VAF values. With regard to 
cutoff values, copy number (CN) ≥ 7 and CN = 0 were used 
for ampli fication and homo deletion, respectively. A paired-end 
mapping analysis and a split-alignment analysis were applied 
for translocation detection. All discordant read-pairs with an 
ab normal insert size or orientation were screened. Soft-clipping 
information of the split-reads was investigated as evidence of 
the genomic rearrangements. The cutoff value of the confident 
translocations was a split-read support count ≥ 3.
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Fig. 1. Establishment of a patient-derived colorectal cancer-liver metastasis xenograft model. (A) Schematic of the patient-
derived tumor xenograft (PDTX) model. (B) Tumor growth PDTX model (F2). Tumor tissues were retransplanted into Balb/c nu/
nu mice (n = 18). Results are presented as mean ± standard deviation.
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RESULTS
Establishing a xenograft model of patient-derived 
CRC-liver metastasis
We collected surgically resected tumor samples from two 
patients with CRC liver metastasis and obtained only one pa-
tient PDTX model. As shown in Fig. 1A, the CRC-liver meta-
stasis patient-derived tumors were transplanted into an NOD/
SCID mouse (the PDTX [F1] model) and re-transplanted into 
nude mice (the PDTX [F2] model). When 2 pieces of the patient-
derived tumor tissue were transplanted into an NOD/SCID 
mouse the day after surgery, the mean latency period required 
to establish the PDTX model (F1) was 60 days. As shown in 
Fig. 1B, the tumor growth was faster in PDTX (F2) than it was 
in PDTX (F1). Therefore, we investigated the histo lo gical mor-
phology and tissue characterization across the generations 
(F0, F1, and F2). Morphologies of F1 and F2 tissues re sembled 
the original patient-derived colon cancer tissues (Fig. 2A). To 
confirm the histological characters of F2, we examined the 
markers of CRC-liver metastasis [8]. In F2 tissues, CK20 (a posi-
tive marker of metastasis) was detected. In contrast, CK7 (a 
nega tive marker of metastasis) was not detected in F2 tissues 
(Fig. 2B). These results indicate that F2 preserved the physio lo-
gical properties of the original patient tumors. 
Genomic features of the PDTX models
To determine where the mutant allele frequencies varied 
across the different passages, we isolated genomic DNA from 
the primary tumor, liver metastasis, and PDTX models (F1/F2). 
Histological assessments reviewed no observable heterogeneity 
among the intragenerational PDTX models. Target exon se-
quencing analysis without high-quality filter conditions re-
Patient (F0) F1 F2
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Fig. 2. Histologic evaluation of a patient-derived colorectal cancer-liver metastasis xenograft model. (A) Histology of a patient 
tumor and of the patient-derived tumor xenograft F1- and F2-derived tumors. Tissue sections were stained with H&E (×400). (B) 
Identification of the metastasis model. Tissue sections were immunostained for CK7 and CK20 (×200). 
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vealed some genetic variations in the 83 cancer-related genes 
across the generations (Table 1A). However, when de novo 
muta tions were defined as a total count of zero in F0 and ≥5 in 
F3, exactly prognostic impact of clone cancer profiling (EGFR, 
KRAS, BRAF, PIK3CA, NRAS, APC and TP53) were detected in 
the paired tumors (Table 1B, C). This result suggests that the 
mutational changes in PDTX were preserved in the early pass-
ages in mice.
Evaluation of chemotherapeutic efficacy using the 
established F2 model
The chemotherapeutic efficacies of commercial anticancer 
agents were evaluated using the PDTX model. To screen the 
responses to anticancer drugs, we selected three anticancer 
drugs that act via different mechanisms. Fortunately, single 
treat ments with all 3 drugs suppressed tumor growth in the F2 
model. As shown in Fig. 3A, tumor proliferation was delayed 
by CDDP, DOX, and DTX. The doubling time of the tumors in 
the control group was 12 days. However, CDDP, DOX, and DTX 
delayed the doubling time by over 1 week. The CDDP-treated 
animals showed evidence of slight recurrence after 3 weeks. 
This result was presumably due to individual administration of 
these anticancer drugs. There was no body weight loss detected 
in any of the 4 groups (Fig. 3B). 
To assess the therapeutic efficacy of these anticancer drugs, 
Ki-67 protein expression levels (a marker of proliferation) were 
measured (Fig. 4A). The Ki-67 expression levels (expressed as 
a percentage of brown spots) were as follows: 26.6% ± 3.9% in 
the control group, 24.7% ± 2.8% in the CDDP group, 21.0% ± 
2.8% in the DOX group, and 19.0% ± 3.4% in the DTX group 
(95% confidence interval). These findings concurred with 
the observed tumor growth delay. We also investigated drug-
induced apoptosis and necrosis. As shown in Fig. 4B, brown 
Table 1A. Comparison of mutations in intragenerational 
patient-derived tumor xenograft (PDTX) models
Gene Human-Colon
Human-
Liver
Liver-PDTX 
(F1)
Liver-PDTX 
(F2)
EGFR
BRAF
TP53
PIK3CA
EGFR
KRAS
GNAS
KDR
FBXW7
APC
MET
ATM
MTOR
ARID1A
MPL
PTCH2
JAK1
INSRR
NTRK1
DDR2
ALK
IDH1
ERBB4
VHL
MLH1
FGRE3
PDGFR3
KIT
KDR
FB
CSF1R
Target exon sequencing analysis shows that there was genetic 
variation across the 83 cancer-related genes.
Table 1B. Comparison of mutations in intragenerational 
patient-derived tumor xenograft (PDTX) models 
Gene Human-Colon
Human- 
Liver
Liver-PDTX 
(F1)
Liver-PDTX 
(F2)
TP53
De novo mutations disappear between F0 and F3 PDTX models 
when the mutations are defined as a total count of zero in F0 and 
≥5 in F3.
Table 1C. Comparison of mutations in intragenerational patient-derived tumor xenograft (PDTX) models
Sample
EGFR
exon 
18
EGFR
exon 
19
EGFR
exon 
20
EGFR
exon 
21
Kras
exon 
2
BRAF
exon 
15
PIK3CA
exon 
9
PIK3CA
exon 
20
NRAS
exon 
2
APC
exon 
16
TP53
exon 
5
TP53
exon 
6
TP53
exon 
7
TP53
exon 
8
Human colon WT WT WT WT WT WT WT WT WT WT WT WT WT G818A
Human liver 
metastasis (F0)
WT WT WT WT WT WT WT WT WT WT WT WT WT G818A
Liver-PDTX (F1) WT WT WT WT WT WT WT WT WT WT WT WT WT G818A
Liver-PDTX (F2) WT WT WT WT WT WT WT WT WT WT C493A WT WT G818A
Colon cancer muta tion profiling was preserved across the PDTX model generations EGFR(18,19,20,21), KRAS(2), BRAF(15), 
PIK3CA(9,20), NRAS, APC(16) and TP53(5,6,7,8).
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spots represented apoptotic cell death. The control group did 
not demonstrate any apoptotic cell death. In contrast, apop-
totic cell death increased in the experimental groups in the 
order CDDP → DOX → DTX. Apoptosis induction is related 
to suppression of the proliferation marker level. Our results 
indi cate that the anticancer drugs inhibited the proliferation of 
CRC-liver metastatic cancer cells and triggered their apoptosis. 
Necrosis was also observed. Gland-substituted foamy histiocytes 
reflect necrotic cell death. Therefore, we considered the gland-
substituted foamy histiocytes as a surrogate of necrosis and 
calculated the ratio of necrotic glands to total glands. As shown 
in Fig. 4C, this ratio was <10% in the anticancer agent-treated 
groups (CDDP 6%, DOX 7%, DTX 8%, respectively). However, the 
ratio was 0% in the control group. 
DISCUSSION
The aim of this study was to evaluate PDTX models to predict 
the response to chemotherapy. Although we attempted to create 
2 models, we only successfully established one CRC-liver meta-
stasis PDTX model. The metastatic lesions had a higher success 
rate than did the primary tumors [14,15].
An evaluation process is needed to suggest chemotherapy 
guide lines based on the sensitivity of CRC-liver metastatic 
tissues to candidate drugs. Recently, techniques have been de-
vised for personalized chemotherapy. The PDTX model, which 
pre serves the physiological properties of patient tumors, is one 
such technique. This model is considered to be a good platform 
for chemosensitivity screening. Therefore, in this study, we 
established a PDTX model using CRC-liver metastatic cancer 
tissues. 
Previous studies have demonstrated that tumorigenesis 
from patient-derived tumor tissues is slower than that from 
pri mary cancer cells or established cancer cell lines [16]. The 
rate of tumorigenesis also depends on the transplanted site 
(e.g., orthotopic or ectopic) and transplantation method [17-19]. 
In this study, we attempted to establish a PDTX model and to 
ensure tumorigenesis using patient-derived tumor tissues in 
NOD/SCID mice using fresh tissue rather than cryopreserved 
tissue. It took 60 days to establish the PDTX F1 model, but less 
time to establish the F2 model. 
The biggest advantage of PDTX models is that they preserve 
the genetic features and microenvironment of a patient’s tumor. 
The histology of the primary tumor was shown to be main-
tained through successive generations in colon cancer [8], which 
is consistent with the results of our study. However, some genes 
were newly identified or disappeared in the PDTX models 
compared to those of the primary tumors, as in a previous 
report [20]. It is possible that heterogeneity in the primary 
tu mor was a result of some mutations being detected in the 
pri mary tumor but not in PDTX, or vice versa. Alternatively, 
selec tion pressures can arise during engraftment into different 
species [20]. Regardless, we demonstrated that well-known can-
cer-related genes are preserved between primary tumor and 
PDXT models. Therefore, the PDTX models could constitute 
pre clinical models that preserve the tumor microenvironment 
of the original patient. 
We evaluated the efficacies of CDDP, DOX, and DTX. Their 
chemosensitivities were compared using tumor growth curves. 
The histological results reflected the modes of cell death 
responsible for tumor suppression. In this study, with regard to 
each drug, the inhibition rates in the PDTX models were similar 
to the tumor volume reduction. We concluded that the CRC-liver 
metastasis PDTX models could be used to deduce information 
regarding the sensitivity to therapeutic agent. 
This study has several limitations. First, evaluations of the 
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Fig. 3. Chemotherapeutic effects of anticancer drugs in the patient-derived tumor xenograft model. (A) Tumor growth delay of 
anticancer drugs. (B) Mouse body weights. Results are presented as mean ± standard deviation (n = 4). CDDP, cisplatin; DOX, 
doxorubicin; DTX, docetaxel.
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therapeutic agents are not ideal given that they were tested in 
immunocompromised mice. Another limitation is that all of 
the PDTX models were established in subcutaneous tissues. 
Prior evidence has suggested that the anatomical site can affect 
tumor biology and its response to chemotherapies. A third 
limitation is that the success rate varied significantly between 
patient tumor characteristics. 
In conclusion, the CRC liver metastasis PDTX models de-
veloped in this study retain the genomic and histological char-
ac teristics of the original patient tumors. By integrating the pre-
dictive value of these models into therapeutic strategies, they 
may be used to develop personalized medicine.
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Fig. 4. Characterization of tumor tissues after treatment with anticancer drugs. (A) Immunostaining with Ki-67 as a marker of 
proliferation. Tissue sections were stained with hematoxylin (×200). (B) Tumor tissue apoptosis was quantified using the TUNEL 
assay. Brown dots represent apoptotic cells. Tissues were observed under a microscope (×400). (C) Tumor necrosis. Tissue 
sections were stained with H&E (×200).
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